Transplantation and Cellular Therapy Meetings | Conference

JSP191 Plus Fludarabine and Low-Dose Irradiation Produces Promising Early Data in MDS/AML

April 27th 2022

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

COVID-19 Vaccine Elicits Varied Immune Responses in cGVHD

April 27th 2022

Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26th 2022

Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.

Iomab-B Yields Beneficial Rates of HCT in Relapsed/Refractory AML

April 26th 2022

The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL

April 26th 2022

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

Itolizumab Generates Rapid Responses, Lowers Surface CD6 Levels in aGVHD

April 25th 2022

Itolizumab decreased levels of cell surface CD6 and increased soluble CD6 in serum in patients with acute graft-vs-host-disease.

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

April 25th 2022

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHL

April 25th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCL

April 25th 2022

Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.

Ruxolitinib Could Prevent Serious GVHD Following Allogeneic HCT

April 25th 2022

The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies

April 25th 2022

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD

April 25th 2022

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL

April 25th 2022

The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma

April 25th 2022

Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.

Dr. Shadman on the Efficacy of MB-106 in Relapsed/Refractory NHL and CLL

April 25th 2022

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Riedell on the Examination of Axi-Cel Therapy in High-Risk LBCL

April 25th 2022

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Frontline Axi-cel Elicits Rapid, Durable Responses in High-Risk Large B-Cell Lymphoma

April 24th 2022

The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.